Myinfla Will Be a New Med for Coronary Artery Disease

December 2021

You'll hear about Myinfla (extended-release colchicine) for patients with coronary artery disease (CAD).

We're used to seeing immediate-release colchicine 0.6 mg for patients with gout.

But there's growing interest in using colchicine for heart patients...to reduce the risk of cardiovascular (CV) events, such as heart attack, stroke, and angina.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Medication Errors Work as a Team to Prevent Vaccine Errors
Cough & Cold Help Demystify Humidifiers and Vaporizers
Asthma Be Prepared for Med Changes for Patients With Asthma
Depression Be Aware of Strategies for Seasonal Affective Disorder
Erectile Dysfunction Listen for Questions About Meds for Erectile Dysfunction
Cardiology Myinfla Will Be a New Med for Coronary Artery Disease
Infectious Diseases Think of Xydalba as Similar to Vancomycin for Resistant Skin Infections
Med Administration Help Patients Prepare to Self-Inject Subcutaneous or IM Meds
Geriatrics Stay Alert for Stimulant Rxs in Older Adults

Myinfla Will Be a New Med for Coronary Artery Disease

Practical advice for a better career, with unlimited access to CE

Table of Contents